

**Ambulatory measures owned and maintained by the AMA Consortium**

Technical specifications: [www.physicianconsortium.org](http://www.physicianconsortium.org)

**Table of AMA Consortium Measures Endorsed by NQF on August 3, 2005**

<b>ASTHMA/RESPIRATORY ILLNESS</b>		
<b>TOPIC</b>	<b>MEASURE</b>	<b>IP Owner</b>
<b>Asthma Assessment</b>	Percentage of patients who were evaluated during at least one office visit for the frequency (numeric) of daytime and nocturnal asthma symptoms	AMA Consortium*
<b>Pharmacologic Therapy</b>	Percentage of all patients with mild, moderate, or severe <i>persistent</i> asthma who were prescribed <i>either</i> the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment	AMA Consortium*
<b>OSTEOARTHRITIS (OA)</b>		
<b>TOPIC</b>	<b>MEASURE</b>	<b>IP Owner</b>
<b>Assessment for Use of Anti-inflammatory or Analgesic OTC Medications</b>	Percentage of patient visits with an assessment for use of anti-inflammatory or analgesic over the counter (OTC) medications	AAOS/AMA Consortium*
<b>Functional and Pain Assessment</b>	Percentage of patient visits with assessment for function and pain	AAOS/AMA Consortium*
<b>Heart Disease</b>		
<b>TOPIC</b>	<b>MEASURE</b>	<b>IP Owner</b>
<b>Coronary Artery Disease (CAD): Symptoms and Activity Assessment</b>	Percentage of patients with coronary artery disease who were evaluated for both level of activity and anginal symptoms during one or more office visits	ACC/AHA/AMA Consortium*

\* Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

**THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND**

© 2005 American Medical Association. All Rights Reserved

Table of AMA Consortium Measures Endorsed by NQF on August 3, 2005		
<b>CAD: Lipid Profile</b>	Percentage of patients with coronary artery disease who received at least one lipid profile (or ALL component tests)	ACC/AHA/ AMA Consortium*
<b>CAD: Drug Therapy for Lowering LDL Cholesterol</b>	Percentage of patients with coronary artery disease who were prescribed a lipid – lowering therapy (based on current ACC/AHA guidelines)	ACC/AHA/ AMA Consortium*
<b>CAD: Antiplatelet Therapy</b>	Percentage of patients with coronary artery disease who were prescribed antiplatelet therapy	ACC/AHA/ AMA Consortium*
<b>CAD: Beta-Blocker Therapy – Prior Myocardial Infarction (MI)</b>	Percentage of patients with coronary artery disease with prior MI at any time who were prescribed beta-blocker therapy	ACC/AHA/ AMA Consortium*
<b>CAD: ACE Inhibitor/ARB Therapy</b>	Percentage of patients with coronary artery disease who also have diabetes and/or LVSD who were prescribed ACE inhibitor/ARB therapy	ACC/AHA/ AMA Consortium*
<b>¥CAD: Smoking Cessation</b>	Percentage of patients with coronary artery disease who were queried one or more times about cigarette smoking	ACC/AHA/ AMA Consortium*
<b>¥CAD: Smoking Cessation Intervention</b>	Percentage of patients with coronary artery disease identified as cigarette smokers who received smoking cessation intervention	ACC/AHA/ AMA Consortium*
<b>Heart Failure (HF): Left Ventricular Function (LVF) Assessment</b>	Percentage of patients with heart failure with quantitative or qualitative results of LVF assessment recorded	ACC/AHA/ AMA Consortium*

\* Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

**THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND**

© 2005 American Medical Association. All Rights Reserved

**Table of AMA Consortium Measures Endorsed by NQF on August 3, 2005**

<b>HF: Weight Measurement</b>	Percentage of patient visits for patients with heart failure with weight measurement recorded	ACC/AHA/ AMA Consortium*
<b>HF: Assessment of Clinical Symptoms of Volume Overload (Excess)</b>	Percentage of patient visits for patients with heart failure with assessment of clinical symptoms of volume overload (excess)	ACC/AHA/ AMA Consortium*
<b>HF: Assessment of Activity Level</b>	Percentage of patient visits for patients with heart failure with assessment of activity level	ACC/AHA/ AMA Consortium* ACC/AHA/ AMA Consortium*
<b>HF: Beta-Blocker Therapy</b>	Percentage of patients with heart failure who also have LVSD who were prescribed beta-blocker therapy	ACC/AHA/ AMA Consortium*
<b>HF: ACE Inhibitor/ARB Therapy</b>	Percentage of patients with heart failure who also have LVSD who were prescribed ACE inhibitor/ARB therapy	ACC/AHA/ AMA Consortium*
<b>HF: Warfarin Therapy for Patients with Atrial Fibrillation</b>	Percentage of patients with heart failure who also have paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy	ACC/AHA/ AMA Consortium*

\* Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

**THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND**

© 2005 American Medical Association. All Rights Reserved

Table of AMA Consortium Measures Endorsed by NQF on August 3, 2005		
<b>HYPERTENSION (HTN)</b>		
TOPIC	MEASURE	IP Owner
<b>Plan of Care</b>	Percentage of patient visits during which either systolic blood pressure $\geq$ 140 mm Hg or diastolic blood pressure $\geq$ 90 mm Hg, with documented plan of care for hypertension	ACC/AHA/AMA Consortium*
<b>PRENATAL</b>		
TOPIC	MEASURE	IP Owner
<b>Anti-D Immune Globulin</b>	Percentage of D (Rh) negative, unsensitized patients who received anti-D immune globulin at 26-30 weeks gestation	AMA Consortium*
<b>Screening for Human Immunodeficiency Virus (HIV)</b>	Percentage of patients who were screened for HIV infection during the first or second prenatal care visit	AMA Consortium*
<b>TOBACCO/ALCOHOL PREVENTION</b>		
TOPIC	MEASURE	IP Owner
<b>¥Tobacco Use</b>	Percentage of patients who were queried about tobacco use one or more times during the two-year measurement period	AMA Consortium*
<b>¥Tobacco Cessation</b>	Percentage of patients identified as tobacco users who received cessation intervention during the two-year measurement period	AMA Consortium*
<b>IMMUNIZATION</b>		
TOPIC	MEASURE	IP Owner
<b>Influenza Vaccination</b>	Percentage of patients who received an influenza vaccination	AMA Consortium*

\* Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

**THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND**

© 2005 American Medical Association. All Rights Reserved

**Measure Deferred to Phase III**

TOPIC	MEASURE	IP Owner
HF: Patient Education	Percentage of patients with heart failure who were provided with patient education on disease management and health behavior changes during one or more visit(s)	ACC/AHA/ AMA Consortium*

¥ Measure Pair

\* Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

**THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND**

© 2005 American Medical Association. All Rights Reserved